To vet potential investors or acquirers, founders should ask them to articulate their vision for the startup's next five years. Hearing their story told through the buyer's eyes reveals the depth of their strategic thinking and helps assess whether their vision aligns with the founder's, ensuring a better post-transaction fit.

Getting a partnership deal done requires more than a good pitch; it requires an internal advocate. Leaders should leverage their network to identify and cultivate a champion inside the target company. This person is critical for navigating internal bureaucracy and pushing the deal over the goal line, as "there's a million ways for deals to die."

The old assumption that small biotechs struggle with commercialization ("short the launch") is fading. Acquirers now target companies like Verona and Intracellular that have already built successful sales operations. This de-risks the acquisition by proving the drug's market viability before the deal, signaling a maturation of the biotech sector.

Merck cited Cedara's extensive, pre-Phase 3 research on pricing and cost-effectiveness as a key factor in its $10B acquisition. This demonstrates that early-stage biotechs can significantly increase their M&A value by proactively building a robust commercial case alongside their clinical development.

Ainsworth believes a responsible biotech entrepreneur envisions the end goal—acquisition or IPO—from day one. At RetroSense, this meant constantly engaging with potential acquirers like Allergan to understand their needs and generate the specific data required to become an attractive M&A target.

Before an LOI, share your high-level vision, then have the target's founders pitch back their own 6- and 12-month post-acquisition roadmap. This pre-commitment exercise reveals true alignment and integration potential far more effectively than traditional diligence, creating a joint vision early on.

Astute biotech leaders leverage the tension between public financing and strategic pharma partnerships. When public markets are down, pursue pharma deals as a better source of capital. Conversely, use the threat of a public offering to negotiate more favorable terms in pharma deals, treating them as interchangeable capital sources.

A Boehringer Ingelheim executive noted a key differentiator of Korean biotechs: they enter initial partnership discussions with a well-defined strategy and understanding of their needs. This "readiness to partner" accelerates deal-making and demonstrates a higher level of business sophistication compared to many global counterparts.

When a potential acquirer calls, the founder's default mode should be information gathering, not pitching. By asking strategic questions ("Who else are you talking to?", "What are your goals?"), founders can extract valuable competitive intelligence about the market and the larger company’s plans, regardless of whether a deal happens.